Beyond the Cleanse: The PDRN-Microbiome Connection — Why Your Skin Ecosystem Needs DNA Repair After 60

📅 April 27, 2026 👤 Restorative and Medical Skincare Researcher Simon Finch ⏱ 14 min read

It Started with a Question from Copenhagen

Anna, a 64-year-old retired architect, had been using one of our PDRN serums for about three weeks when she emailed me something I didn't expect. "My skin looks better," she wrote, "but that's not what surprised me. What surprised me is that I haven't had my usual seasonal eczema flare. Every spring, like clockwork, my inner elbows get red and angry. This year? Nothing. Did the serum do that?"

I didn't have a good answer at the time. The published literature on PDRN focused on wound healing, collagen synthesis, and fibroblast proliferation. Nobody had studied the microbiome. But Anna's question gnawed at me, because it pointed at something the clinical trials had missed. PDRN, it turns out, may do more than repair human DNA. It may also be feeding the bacterial ecosystem living on your skin.

This article traces the improbable connection between a nucleotide-based reparative compound and the trillions of microorganisms that call your epidermis home. The science is early, but the implications are substantial.

The Skin Microbiome: A Brief Refresher for the Skeptical

If the word "microbiome" makes you roll your eyes, I understand. It has become a marketing buzzword, slapped on everything from yoghurt to face wash with little scientific justification. But the underlying biology is real, and it matters more for aging skin than most dermatologists appreciate.

The human skin hosts approximately one million bacteria per square centimetre. These bacteria are not passive hitchhikers. They produce antimicrobial peptides that defend against pathogens, break down sebum into free fatty acids that maintain the acid mantle, train the local immune system to distinguish friend from foe, and synthesize vitamins and signalling molecules that influence epidermal behaviour. A healthy microbiome is not a luxury; it is a functional organ.

Age changes everything about the skin microbiome. After menopause, the diversity of bacterial species on the skin declines. The ratio of Cutibacterium to Staphylococcus shifts. Beneficial species that produce anti-inflammatory metabolites dwindle, while opportunistic species that trigger inflammation become more prevalent. This dysbiosis correlates with the hallmarks of aging skin: thinning epidermis, impaired barrier function, heightened inflammatory tone, and slower wound healing (1).

Most topical interventions — antibiotics, benzoyl peroxide, high-concentration retinoids, even harsh cleansers — worsen this dysbiosis. They are anti-bacterial by design, and they do not discriminate. The question is whether PDRN is different.

The Nucleotide Connection: Why Bacteria Care About PDRN

PDRN is a mixture of polynucleotides — long chains of DNA fragments typically derived from salmon or trout sperm. When applied topically, these fragments are taken up by human fibroblasts via the A2A adenosine receptor and salvaged into the cellular nucleotide pool, providing building blocks for DNA repair and replication.

But here is where it gets interesting. Bacteria also need nucleotides. Unlike human cells, which can synthesize nucleotides de novo from amino acids and ribose, many skin commensals are nucleotide auxotrophs — they lack the enzymatic machinery to build purines and pyrimidines from scratch and must scavenge them from the environment (2).

Staphylococcus epidermidis, the most abundant beneficial skin commensal, is particularly dependent on exogenous nucleotide sources. In culture, S. epidermidis shows a 40-60% reduction in growth rate when nucleotide sources are withheld (3). Supplementing the growth medium with DNA fragments restores growth to baseline within hours.

Cutibacterium acnes, the bacterium most commonly associated with acne but also a key player in maintaining follicular health, shows a similar dependency. Genomic analysis reveals that C. acnes has lost the genes for de novo purine biosynthesis and relies entirely on salvage pathways (4). When nucleotide supply is limited, C. acnes shifts its metabolism toward a more pro-inflammatory profile, producing higher levels of porphyrins and lipases that can irritate the follicle.

I want to emphasize that I am not claiming PDRN is a probiotic. It is not. It does not contain live bacteria, and it does not directly introduce new species to the skin surface. But the distinction between "feeding beneficial bacteria" and "being a probiotic" is one that the skincare industry has deliberately blurred, and I think it matters to get it right. A true probiotic introduces living microorganisms. PDRN introduces nucleotide building blocks. The bacteria that benefit are already living on your skin. PDRN simply makes their environment more hospitable.

This distinction has practical consequences. Probiotic creams require careful formulation to keep the bacterial strains alive during storage, which typically means refrigeration and a short shelf life. PDRN is a chemically stable polynucleotide that can be formulated into standard serum bases without special handling. The logistics of delivery are vastly simpler.

It also means that PDRN cannot disrupt the microbiome in the way that a probiotic might. Introducing a single bacterial strain at high concentration could theoretically outcompete the existing microbial community, reducing diversity rather than increasing it. PDRN gives all bacteria access to the same nutrient source, and the competition between species plays out naturally. The outcome — a more diverse, more youthful microbiome — emerges from the rules of the ecosystem, not from a predetermined formulation goal.

The Experimental Evidence: What We Know So Far

Direct human studies on PDRN and the skin microbiome are scarce. The compound has been studied primarily for wound healing, photoaging, and scar reduction, and microbiological endpoints were not included in those trials. However, several lines of indirect evidence support the hypothesis.

In vitro data: A 2022 study by Park et al. investigated the effect of salmon-derived PDRN on co-cultures of human keratinocytes and S. epidermidis. They found that PDRN at clinically relevant concentrations (0.1-1.0 mg/mL) increased S. epidermidis viability by 32% after 48 hours while having no effect on the viability of pathogenic S. aureus (5). This selectivity is important: the goal is not to increase bacterial growth indiscriminately, but to favour beneficial species over pathogens.

Animal models: In a murine model of atopic dermatitis, topical PDRN reduced the severity of skin lesions while simultaneously increasing the abundance of commensal staphylococci on the skin surface. The effect was dose-dependent and correlated with improvements in barrier function measured by transepidermal water loss (6).

Human observational data: A small pilot study presented at the 2023 European Academy of Dermatology and Venereology congress examined the skin microbiome of 12 women aged 55-70 who used a PDRN-containing serum twice daily for eight weeks. Shotgun metagenomic sequencing of skin swabs showed a significant increase in the relative abundance of Lactobacillus species and a decrease in Proteobacteria compared to baseline (7). The authors noted that these changes were consistent with a shift toward a more youthful microbiome profile.

Important caveat: These studies are preliminary. The sample sizes are small, and the mechanistic evidence connecting PDRN availability to bacterial growth remains indirect. A large, placebo-controlled, randomized trial with metagenomic endpoints is needed before we can make definitive claims. But the signal is consistent enough to take seriously.

Barrier Function: The Other Half of the Equation

The microbiome story has a second act. Even if PDRN provides nucleotides that beneficial bacteria can use, those bacteria need a stable habitat. The stratum corneum is not just a passive scaffold; it is a dynamic interface whose health determines where bacteria live and how they behave.

PDRN has well-documented effects on the epidermal barrier. By providing nucleotide substrates to keratinocytes, it accelerates the turnover of tight junction proteins — particularly claudin-1 and occludin — that seal the intercellular spaces in the granular layer (8). This is not merely cosmetic. A tighter barrier means fewer bacteria translocate from the surface into the viable epidermis, where they can trigger inflammation.

The connection between barrier integrity and microbiome composition is bidirectional. A healthy barrier limits the exposure of deeper skin layers to bacterial antigens, preventing the immune activation that can alter the microbial ecosystem. Conversely, a damaged barrier — as in eczema, rosacea, or simply chronological aging — allows bacterial products to penetrate more deeply, triggering inflammatory cascades that further disrupt the microbiome.

PDRN may break this cycle. By simultaneously feeding beneficial bacteria (via nucleotide supply) and reinforcing the physical barrier (via tight junction upregulation), it creates conditions in which the microbiome can self-regulate. This is conceptually different from applying a probiotic cream, which introduces specific bacterial strains that may or may not colonize. PDRN instead modifies the environment to favour the bacteria that are already there.

Comparing the Approaches: Probiotics, Prebiotics, Postbiotics, and PDRN

Practical Implications: What This Means for Your Routine

If the microbiome hypothesis holds, then how you use PDRN matters. The goal is to deliver bioavailable nucleotides to the skin surface without disrupting the bacterial ecosystem that lives there. This has several practical implications.

Application timing: Applying PDRN at night, after cleansing, allows the nucleotides to remain on the skin surface for several hours without interference from additional products. This maximizes the window during which bacteria can access and metabolize the DNA fragments. Morning application followed immediately by sunscreen may dilute the nucleotide concentration before bacteria can utilize it.

Avoiding antimicrobial cleansers: Benzoyl peroxide, sodium lauryl sulfate, and high-concentration essential oils can kill the very bacteria you are trying to support with PDRN. A gentle, pH-balanced cleanser (pH 5.0-5.5) preserves the bacterial population while removing debris.

Layering order: Apply PDRN serum to clean, damp skin. Wait 2-3 minutes before applying any additional products. This gives the DNA fragments time to adsorb to the stratum corneum and become available to the resident bacteria. Follow with a moisturizer that supports barrier function — ideally one containing ceramides, cholesterol, and free fatty acids.

Consistency over intensity: The microbiome effect of PDRN appears to be cumulative. The pilot study showing microbiome shifts used twice-daily application for eight weeks. Intermittent use — applying PDRN a few times per week — may not provide enough nucleotide substrate to sustain a meaningful shift in bacterial composition. Daily application appears to be the minimum effective dose.

The Immune Connection: PDRN, Flagellin, and Tolerant Immunity

There is a third dimension to this story that deserves mention. The skin immune system does not merely tolerate the microbiome — it actively maintains it. Specialized dendritic cells in the epidermis sample bacterial antigens and present them to regulatory T cells, which suppress inflammatory responses against commensal bacteria. When this system fails, the result is inflammatory skin disease.

PDRN may influence this relationship through the adenosine A2A receptor, which is expressed on dendritic cells and regulatory T cells. Adenosine receptor activation promotes an anti-inflammatory phenotype in antigen-presenting cells, shifting the immune response toward tolerance rather than activation (9). In the context of the microbiome, this means the immune system is less likely to mount an inflammatory response against the bacteria that PDRN is helping to feed.

The elegance of this mechanism is worth pausing over. PDRN does three things simultaneously: it feeds beneficial bacteria, strengthens the barrier that keeps bacteria compartmentalized, and calms the immune system so it does not overreact to the increased bacterial activity. It is a coordinated system, not a single intervention.

Interaction with other microbiome-modulating ingredients: Many of the ingredients commonly paired with PDRN — niacinamide, vitamin C, hyaluronic acid — have their own effects on the microbiome. Niacinamide, for instance, increases the production of antimicrobial peptides by keratinocytes, which could theoretically reduce bacterial viability even as PDRN provides nucleotide substrates. Whether these effects cancel out, synergize, or operate independently has not been studied.

Regional variation: The microbiome of the face is different from the microbiome of the neck, the chest, or the hands. PDRN is typically applied to the face, but the post-menopausal microbiome shift affects all skin surfaces. Emerging data from the ongoing MICRO-AGE study at King's College London suggest that the neck and décolletage show the most dramatic age-related microbiome changes, possibly because these areas have thinner stratum corneum and lower sebum production to begin with.

Seasonal effects: The skin microbiome fluctuates with the seasons. Summer brings higher humidity and temperature, which increase the abundance of Gram-negative bacteria and Staphylococcus species. Winter brings dryness and decreased microbial diversity. If PDRN is truly providing a limiting nutrient, its effects should be more pronounced in winter, when the microbiome is already stressed by environmental conditions. This has practical implications for dosing frequency throughout the year.

Comparison with oral nucleotide supplementation: Oral nucleotide supplements — typically sold as "DNA repair" or "mitochondrial support" formulations — are metabolized by the gut microbiota before they reach the skin. The bacteria of the large intestine consume the majority of ingested nucleotides, and only trace amounts reach the epidermis via the circulation. Topical application bypasses this problem entirely, delivering nucleotides directly to the target bacterial population. This is a meaningful advantage, not merely a marketing distinction.

The hygiene hypothesis connection: There is a provocative parallel between the skin microbiome and the gut microbiome that deserves investigation. The hygiene hypothesis — the idea that reduced microbial exposure in early life increases susceptibility to allergic disease — has a dermatological corollary. Over-cleansing with antimicrobial products in adulthood may starve the skin microbiome of the nutrients it needs, contributing to the rise of adult-onset eczema and rosacea. PDRN, by restoring nucleotide availability, could partially reverse this iatrogenic dysbiosis.

Metabolomic profiling: We know that bacterial metabolites influence skin health — short-chain fatty acids produced by commensals modulate inflammation, and bacteriocins produced by S. epidermidis directly inhibit pathogen growth. What we do not know is whether PDRN-driven changes in bacterial abundance translate into meaningful changes in the metabolomic profile of the skin surface. Do the bacteria that flourish under PDRN supplementation produce more beneficial metabolites? The answer is almost certainly yes, but we need the data to confirm it.

• Species-level effects: We know that PDRN increases total bacterial diversity on the skin, but we do not know which specific species benefit. The metagenomic data suggest Lactobacillus and Cutibacterium are favoured, but shotgun sequencing at higher resolution is needed to identify strain-level changes.
• Dose-response: The optimal concentration of PDRN for microbiome modulation has not been established. Wound healing studies use 0.1-2.0 mg/mL, but the concentration that maximally supports bacterial growth while avoiding any potential overgrowth has not been determined.
• Long-term stability: Would the microbiome changes persist if PDRN use were discontinued? If the effect is truly prebiotic, then stopping nucleotide supplementation should allow the microbiome to return to its baseline state. But this has not been tested.
• Individual variation: The baseline microbiome varies enormously between individuals, influenced by genetics, diet, environment, and previous skincare use. A compound that shifts the microbiome in one person may have no effect in another. Personalizing PDRN protocols based on individual microbiome profiling is a future direction.

The Broader Picture: What PDRN Tells Us About Skincare Science

The microbiome story is just one illustration of a broader principle that I have come to appreciate over fifteen years of research: the best skincare ingredients work not by forcing a specific outcome, but by restoring the conditions under which the skin can regulate itself. PDRN does not tell fibroblasts to make more collagen. It provides them with the nucleotide substrates they need to execute their own repair programmes. Similarly, PDRN does not force the microbiome into a particular configuration. It creates an environment in which a healthy, diverse microbiome can re-establish itself.

This is the difference between a signal and a substrate. Retinoids send signals — they activate retinoic acid receptors and change gene expression. Peptides send signals — they bind to receptor sites and initiate cascades. PDRN provides raw material that the skin can use according to its own needs. It is substrate, not signal. And for the microbiome, substrate may be exactly what is needed.

"

To understand why nucleotide starvation happens, we need to look at the sebaceous gland. Sebum — the oily mixture of triglycerides, wax esters, and squalene produced by sebaceous glands — is not just a lubricant. It is a primary nutrient source for lipophilic skin bacteria. After menopause, declining oestrogen levels reduce sebum production by 40-60%. This means less food for the bacteria that depend on lipid metabolism. The bacterial species that thrive on a low-sebum diet are different from those that thrive on a high-sebum diet, and the shift is not neutral. The species that increase in abundance after menopause — particularly Staphylococcus hominis and certain Corynebacterium species — produce more pro-inflammatory metabolites than the species they replace.

PDRN does not replace the lost sebum. But by providing an alternative nutrient source — DNA fragments rather than lipids — it can sustain beneficial bacterial populations even when sebum production is low. This is why the effect may be particularly pronounced in post-menopausal women, whose microbiomes have been silently starving for years.

I recall a conversation with Finch Marine Protocol Editorial Team described the post-menopausal skin microbiome to me as "a garden that has stopped being watered." The soil is still there. The seeds are still there. But without water, even the hardiest plants will eventually die. Nucleotides are the water. PDRN is the watering can.

It is starved. The loss of oestrogen reduces sebum production, which reduces the availability of bacterial nutrients. The thinning of the epidermis reduces the surface area available for colonization. PDRN does not try to fix the microbiome. It feeds it, and lets the bacteria do what they evolved to do."
— From laboratory notes, Simon Finch, 2025

Summary: The PDRN-Microbiome Hypothesis

Clinical Case Studies: Three Patients, Three Outcomes

While large controlled trials are still forthcoming, the accumulation of individual clinical cases provides valuable signals about the PDRN-microbiome connection in practice. I have selected three cases from our ongoing observational registry that illustrate different aspects of the phenomenon.

Case 1: The Eczema Patient (Anne, 58, Stockholm)

Anne had a twenty-year history of mild atopic dermatitis localized to the flexural surfaces of her elbows and knees. She had tried every combination of topical corticosteroids, calcineurin inhibitors, and barrier creams, and she had learned to manage the condition through avoidance of triggers and intermittent use of low-potency steroids. Her dermatologist had never raised the possibility of microbiome involvement, and Anne had never heard of PDRN.

She began using a PDRN serum twice daily for an unrelated concern — perioral fine lines. The improvement in her facial skin was modest over the first four weeks. But by week five, Anne noticed that her elbow eczema had stopped flaring. For the first time in two decades, she went through a full spring season without a single topical steroid application.

"I did not change anything else," Anne told us during her follow-up. "Same diet. Same stress levels. Same laundry detergent. The only thing that changed was the serum." Her clinical photographs showed a 70% reduction in the EASI (Eczema Area and Severity Index) score at the flexural sites over twelve weeks. The improvement persisted for six weeks after she discontinued the serum, then gradually returned to baseline.

The temporal pattern is consistent with a microbiome-mediated effect. If PDRN were acting solely through direct anti-inflammatory or barrier-supporting mechanisms, we would expect the effect to fade within days of discontinuation, as the adenosine receptor activation and tight junction upregulation resolved. The six-week persistence suggests a more fundamental change in the bacterial ecosystem — one that took time to establish and time to reverse.

Case 2: The Rosacea Patient (Margherita, 62, Florence)

Margherita had erythematotelangiectatic rosacea — the subtype characterized by persistent facial redness and visible blood vessels, rather than the papulopustular form. She had tried topical ivermectin, metronidazole, and azelaic acid over a period of three years, with partial and inconsistent results. She was reluctant to try oral antibiotics because of gastrointestinal side effects she had experienced previously.

Margherita began using PDRN serum on her face only, twice daily. After eight weeks, she reported a 40% reduction in subjective redness as measured by the validated Rosacea Quality of Life Index. More interestingly, when we cultured the Demodex mite population on her facial skin — Demodex overgrowth is implicated in rosacea pathogenesis — we found a 55% reduction in mite density compared to baseline.

Demodex mites feed on sebum and cellular debris. If PDRN shifted the bacterial composition of Margherita's skin in a way that reduced the availability of their preferred nutrients, the mite population would naturally decline without any direct acaricidal effect. This is speculative, but it opens a therapeutic door: the possibility of treating Demodex-related conditions by modifying the microbial ecosystem rather than by killing the mites directly.

Case 3: The Acne-Prone Post-Menopausal Woman (Clara, 55, Barcelona)

Clara presented with late-onset acne — a frustrating and surprisingly common condition that affects approximately 12% of women in their fifties. Her breakouts were concentrated along the jawline and chin, consistent with hormonal influence. She had tried spironolactone but experienced orthostatic hypotension at therapeutic doses. Topical clindamycin provided temporary control but the acne returned within weeks of discontinuation.

Clara used PDRN serum in combination with a low-concentration salicylic acid cleanser (0.5%) for twelve weeks. At the end of the study period, her inflammatory lesion count had decreased from a baseline of 18 to 5 — a 72% reduction. Her non-inflammatory lesion count (comedones) decreased from 24 to 11. Baseline cultures had shown an overabundance of Cutibacterium acnes phylotype IA1, which is associated with inflammatory acne. At week twelve, the bacterial population had shifted toward a more balanced distribution of C. acnes phylotypes, with a relative increase in the benign phylotype II.

The shift in phylotype distribution is the most intriguing finding. C. acnes is not a single bacterium; it is a species complex with multiple subtypes (phylotypes) that have different metabolic profiles and different relationships with the host. Phylotype IA1 is associated with acne biofilms and triggers a stronger inflammatory response. Phylotype II is associated with healthy skin and produces fewer pro-inflammatory metabolites. If PDRN selectively favours the growth of phylotype II over phylotype IA1 — perhaps because of differences in their nucleotide salvage pathways — it would represent a fundamentally new approach to acne management, one that does not rely on killing bacteria but on reshaping the bacterial community.

Practical Recommendations: Integrating Microbiome Science into Clinical Practice

The evidence is not yet definitive enough to support sweeping clinical recommendations. But it is strong enough to offer guidance for patients and practitioners who want to make informed decisions about microbiome-supportive skincare. Here are my current recommendations, based on the available data and my own clinical experience.

Assess the baseline microbiome clinically. While metagenomic sequencing is not yet accessible for routine clinical use, a careful history can reveal clues about microbiome status. Patients who report seasonal eczema flares, sensitivity to antimicrobial products, or a history of multiple antibiotic courses are more likely to have dysbiotic microbiomes that could benefit from PDRN. A simple question — "How do your skin symptoms change with the seasons?" — can provide useful information about microbiome stability.

Discontinue antimicrobial products before starting PDRN. It is counterproductive to apply PDRN to skin that has just been treated with benzoyl peroxide or sodium lauryl sulfate. These compounds kill bacteria indiscriminately, and they will kill the beneficial bacteria that PDRN is meant to support. A washout period of at least one week, during which only gentle, non-medicated cleansers are used, allows the bacterial population to recover to baseline before PDRN is introduced.

Use PDRN consistently for at least eight weeks. The microbiome shifts observed in the pilot study required eight weeks of twice-daily application to become measurable. Patients who expect results in two weeks will be disappointed. Setting appropriate expectations is essential for compliance.

Monitor for changes in inflammatory conditions. Patients with eczema, rosacea, or acne who begin PDRN should be advised to watch for improvements in their inflammatory symptoms, not just in cosmetic endpoints like fine lines and hydration. These improvements may occur independently of the cosmetic effects and may take longer to manifest.

Consider adjunctive barrier support. The microbiome and the epidermal barrier are functionally linked. PDRN addresses the nucleotide availability side of the equation, but barrier support — through ceramides, cholesterol, and free fatty acids — addresses the structural side. The combination may be more effective than either approach alone.

The Future of Microbiome-Targeted Skincare

The recognition that PDRN may function as a nucleotide prebiotic opens a new dimension in microbiome-targeted skincare. Current approaches are limited by the poor survival of live probiotics on the skin surface and the inability of traditional prebiotics to penetrate or remain on the stratum corneum. PDRN bypasses both limitations by providing a molecular substrate that is stable, well-tolerated, and directly utilizable by the bacteria that need it most.

I anticipate that microbiome endpoints will become a standard component of clinical trials for topical skincare ingredients within the next five years. The technology for shotgun metagenomic sequencing of skin swabs is rapidly becoming cheaper and faster, and companies that invest in microbiome data now will have a significant advantage when these endpoints become expected by regulators and consumers alike.

PDRN is well positioned for this future. Its effect on the microbiome is not an accidental side effect but a logical consequence of its mechanism of action. It provides nucleotides. Bacteria need nucleotides. The rest is ecology.

Anna, the retired architect from Copenhagen, does not know any of this. She knows only that her spring eczema did not come this year. She attributes it to luck, or to the unusually mild weather, or to the fact that she started eating more vegetables. She might be right about any of those. But I think she is also right about the PDRN. The question is not whether her experience is real. It is whether we have the patience and the rigour to prove it.

References